Proactive Investors - Run By Investors For Investors

Alliance Pharma on target to meet market expectations after a solid first-half

Revenues were up 10% in the first six months of the year as the company's star brands performed strongly
Vanousse advert
Vamousse, a head lice treatment, is one of the company's international star brands

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical group, said it is trading in line with expectations.

In an update, it said revenues for the six months ended June 30 rose 10% to £54.4mln, though trading profit tracked at a slightly slower pace due largely to the phasing of marketing spend.

The company’s star international brands MacuShield, Vamousse and Kelo-Cote delivered “strong performances”, investors were told. The latter, a treatment for scarring, saw its sales increase 77% to almost £11mln.

Revenues from what Alliance calls local hero brands were in line with forecasts.

Cash flow remained strong

The company said its top line was negatively affected by currency fluctuations to the tune of £900,000.

Underlying free cash flow was £10.1mln, while net debt increased by £14mln to £86.3mln as it funded acquisitions such as the purchase of medicated anti-dandruff shampoo, Nizoral.

The company said it expects to launch anti-nausea treatment Xonvea in the UK in the autumn.

“On the basis of trading in the year to date, the board expects revenue and underlying profit before tax for the current financial year to be in line with expectations,” the market was told.

View full APH profile View Profile

Alliance Pharma PLC Timeline

Newswire
January 21 2019

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
1537236236_main-better-use.jpg
September 17 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use